A cardiovascular outcomes trial has already shown a reduction in cardiovascular events, but not deaths.
The findings suggest identifying children at risk of T2D and fixing their sleep could be a low-cost way to head off type 2 diabetes.
Louis S. Christos, RPh, offers a payer perspective regarding the role of glucagon-like peptide-1 receptor agonist/insulin combinations and discusses the importance of real world evidence.
The connection between diabetes and cardiovascular disease is well-known, but a new study gets at the mechanism of how this occurs.
Value-based purchasing is happening and Glytec is participating in this new and transitioning form of care, says Andrew Rhinehart, MD, chief medical officer at Glytec. This extension of care beyond the hospital for diabetes needs is promising in producing better patient outcomes.


April 12th, 2014
Hershey, PA
May 22nd to 25th , 2014
Fort Lauderdale, FL
August 14th to 16th, 2014
Stowe, VT
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST